| Literature DB >> 34988369 |
Noor Ahmed Hussain1, Francisco C Figueiredo2, Che J Connon3.
Abstract
Human corneal endothelium (HCE) is a single layer of hexagonal cells that lines the posterior surface of the cornea. It forms the barrier that separates the aqueous humor from the rest of the corneal layers (stroma and epithelium layer). This layer plays a fundamental role in maintaining the hydration and transparency of the cornea, which in turn ensures a clear vision. In vivo, human corneal endothelial cells (HCECs) are generally believed to be nonproliferating. In many cases, due to their nonproliferative nature, any damage to these cells can lead to further issues with Descemet's membrane (DM), stroma and epithelium which may ultimately lead to hazy vision and blindness. Endothelial keratoplasties such as Descemet's stripping automated endothelial keratoplasty (DSAEK) and Descemet's membrane endothelial keratoplasty (DEK) are the standard surgeries routinely used to restore vision following endothelial failure. Basically, these two similar surgical techniques involve the replacement of the diseased endothelial layer in the center of the cornea by a healthy layer taken from a donor cornea. Globally, eye banks are facing an increased demand to provide corneas that have suitable features for transplantation. Consequently, it can be stated that there is a significant shortage of corneal grafting tissue; for every 70 corneas required, only 1 is available. Nowadays, eye banks face long waiting lists due to shortage of donors, seriously aggravated when compared with previous years, due to the global COVID-19 pandemic. Thus, there is an urgent need to find alternative and more sustainable sources for treating endothelial diseases, such as utilizing bioengineering to use of biomaterials as a remedy. The current review focuses on the use of biomaterials to repair the corneal endothelium. A range of biomaterials have been considered based on their promising results and outstanding features, including previous studies and their key findings in the context of each biomaterial.Entities:
Keywords: Descemet’s membrane (DM); biomaterials; cornea; corneal transplantation; human corneal endothelial cells (HCECs); scaffold; tissue engineering
Year: 2021 PMID: 34988369 PMCID: PMC8721373 DOI: 10.1177/25158414211058249
Source DB: PubMed Journal: Ther Adv Ophthalmol ISSN: 2515-8414
Figure 1.Diagram of the human cornea location and structure.
Source: Author’s illustration.
Figure 2.Overview of the concept of corneal bioengineering and regeneration therapy of human corneal endothelial cells (HCECs), which ultimately is aimed at alleviating the global shortage in donor cornea tissues. General steps have been summarized. (a) The corneal endothelial cell sources: primary cells isolated from a donor cornea, immortalized cell lines, or stem cells. (b) In vitro cell expansion is the next step with the necessity to maintain healthy phenotype and morphology. The delivery system of the expanded corneal endothelial cells to the posterior corneal surface is achieved using (c) cell injection therapy or (d) using various types of biomaterials to fabricate corneal endothelial cell scaffold. (e) The implantation stage of the cultured scaffold into the anterior chamber through a similar DMEK/DSAEK transplantation. (f) Parallel studies on the scaffold are carried out to investigate whether the scaffold is working effectively. (g) Corneal bioengineering and regeneration therapy can alleviate the shortage of native corneas and help improve the quality of life for many patients who are waiting their turn for cornea tissue transplantation.
Source: Author’s illustration.
Figure 3.(a) The structure of human AM, and the composition of extracellular matrix for each layer (Source: Leal-Marin and colleagues ). (b) The illustration displays placenta and fetal membranes. (c) The fetal bag (membranes) can be viewed on the placenta with a surgical incision noticeable. (d) An isolate and dispersed human AM is seen. The circle shows the placental human AM (proximal) area and the stars show the peripheral human AM (distal) areas (Source: Grémare and colleagues ).
Figure 4.Diagram showing the general approach for using decellularized tissues for corneal endothelial cells’ bioengineering.
Source: Author’s illustration.
Figure 5.Analysis by scanning electron microscopy of collagen gel shows the difference between (a) uncompressed gel and (b) compressed gel. Collagen fibers on the surface of the uncompressed gel are displayed in a disorganized and very loosely arranged manner, whereas the collagen fibers in the compressed gel are more densely packed and homogeneous.
Source: Mi and colleagues.
Figure 6.Photos show the high transparency of ‘pure chitosan’ and largely high transparent ‘blended chitosan with polycaprolactone’ (PCL25, PLC50, PCL75, but not PCL100), comparing with tissue culture polystyrene (TCPS) plates.
Source: Wang and colleagues.
Figure 7.Figure (a) shows agarose membrane is transparent and robust enough to be handled with a pair of forceps and (b) Despite the thickness was being ~8 mm, the conjugated agarose gel with fish-derived gelatin (AG) showed excellent transparency (the red star indicates the agarose gel).
Source: Seow and colleagues.
Figure 8.(a) Poly-ε-lysine hydrogel forms a thin transparent film. (b) Microporous structure of the poly-ε-lysine hydrogel under atomic force microscope (AFM). (c) Poly-ε-lysine hydrogels can be manipulated easily using forceps.
Source: Kennedy and colleagues.
Summary of the advantages and limitations of each biomaterial which has been used as scaffold-based tissue engineering for the corneal endothelium.
| Biomaterial | Advantages | Limitations | Mechanical properties | Transparency | Used corneal endothelial cell types | |
|---|---|---|---|---|---|---|
| AM | Naturally biocompatible material
| Low biomechanical consistency
| The fluctuation of mechanical stability such as elasticity, stiffness, and tensile strength is due to the composition of the placenta,
| AM was found to be up to 85% as transparent as the human cornea (according to its original location from within the fetal sac and its method of preservation, as either can influence corneal transparency)
| HCECs
| Rabbit model
|
| Decellularized tissues: (a) decellularized corneal stroma | Generally, natural material, the best model of a given tissue’s native microenvironment (3D) in terms of providing growth/behavioral cues
| Limitation of mechanical properties | ||||
| Decellularized corneal stroma provides a unique ECM organization that supports cell functions, including cell adhesion, proliferation, and cell–cell interactions through offering appropriate mechanical properties and essential biological properties
| The decellularized human corneal stroma has provided acceptable mechanical properties in terms of tensile strength and Young’s modulus which were similar to the mechanical properties of the native corneal stroma
| Decellularized stroma has acceptable transparency and it maintained a 90% transparency after decellularization
| HCECs[ | Rabbits
| ||
| (b) Decellularized human crystalline lens capsules
| Biodegradation results of the LC was acceptable (after 13 hrs) compared with DM (after 17 h)
| Limitation in permeability test with corneal endothelial cultures | None | LC has excellent transparency even after the decellularization process
| Primary HCEnCs
| None |
| (c) Decellularized DS from porcine cornea
| Obtaining ultra-thin DS graft (approximately 99 μm in the dry graft) compared with ultra-thin and standard DSEK (which are less than 100 and 200 μm, respectively). | Limitation in permeability test with corneal endothelial cultures | None | Compared with the control, the dry DS graft displayed high transparency (~92%) after cell seeding
| hCEC-B4G12 cell line
| Porcine eye
|
| (d) Decellularized bovine corneal posterior lamellae
| Inexpensive
| Xenogeneic substrate need | None | Semitransparent to cloudy after decellularization process. Using 100% glycerol has changed the transparency into almost complete transparency
| Human corneal endothelial cells
| None |
| Silk fibroin | Natural fibrous protein
| Inadequate elasticity | Has excellent mechanical robustness
| Excellent transparency[ | B4G12 endothelial cell line
| Rabbit model
|
| Gelatin | Natural material | Lack of mechanical strength
| GelMA+ has over eightfold increase in mechanical strength compared with regular GelMA
| Excellent transparency | Human corneal endothelial cells
| None |
| Collagen | Multisources protein | Risk of disease transmission and allergic reactions due to its source from animal tissues
| Lack of mechanical stiffness
| Human corneal endothelial cells
| Rabbit
| |
| (a) Plastic compressed type I collagen gel | The compressed gels have similarity in structure and transparency with the normal corneal stroma
| Improved mechanical prosperities
| Transparency
| |||
| (b) Compressed collagen using RAFT method
| There is reduced variability among batches during production | Biodegradability time | The mechanical strength of these compressed gels is improved and sufficient to withstand the manipulation without rupture
| None | Human corneal endothelial cells
| None |
| Chitosan blends | Low costs
| Poor solubility
| Blending with other materials can improve its mechanical properties[ | Good transparency
| Bovine corneal endothelial cells[ | None |
| Agarose | Natural material | Poor cell adhesive ability due to lacking appropriate chemical groups for enhancing cells’ attachment
| Strong mechanical properties
| Excellent optical transparency
| Rabbit corneal endothelial cells
| None |
| Poly-ε-lysine (pεK) | Being a synthetic material, it can be tightly controlled to produce customized characteristics of scaffold
| Further | Sufficient mechanical properties for handling during surgery
| Excellent transparency[ | Human corneal endothelial cell line (HCEC-12)
| None |
AM, amniotic membrane; DM, Descemet’s membrane; DS, Descemet stripping; ECM, extracellular matrix; Descemet’s stripping endothelial keratoplasty DSEK; HCECs, human corneal endothelial cells; HCEnCs, human corneal endothelial cells; HLA, human leukocyte antigen; LC, lens capsule; RAFT, Real Architecture For 3D Tissues; RGD, arginine-glycine-aspartic acid.